boston skyline - thinkstock

Sanofi-Aventis Sees A Bright Future In Boston-Cambridge

Sanofi CEO Chris Viehbacher says research departments have been consolidated here to be near universities.


(AP Graphic

It’s A Done Deal For Genzyme

After nine months of denials, rejection, bickering and finally, discussion, French pharmaceutical company Sanofi-Aventis of Paris has signed a deal to buy Genzyme of Cambridge for $20.1 billion plus other milestone payments in the future.


Genzyme headquarters

Genzyme Sold To Sanofi-Aventis In $20 Billion Deal

Cambridge-based biotechnology company Genzyme is being bought by French drug maker Sanofi-Aventis for $20.1 billion, ending months of corporate haggling.


Genzyme headquarters

Genzyme Rejects Latest Sanofi Offer

Sanofi-Aventis extended its unsolicited $18.5 billion takeover offer for Cambridge biotech company Genzyme Corp. Monday.


Talk of possible Genzyme sale heating up

The Cambridge biotech company is being pursued by French drug company Sanofi-Aventis.  WBZ New England Business Editor Anthony Silva talked with Ken Bredemeier,  senior health care reporter at The Deal.